

World Journal of *Gastroenterology*

World J Gastroenterol 2018 March 7; 24(9): 957-1062



**REVIEW**

- 957 Quantitative and noninvasive assessment of chronic liver diseases using two-dimensional shear wave elastography

Xie LT, Yan CH, Zhao QY, He MN, Jiang TA

ORIGINAL ARTICLE**Basic Study**

- 971 Can bacterial virulence factors predict antibiotic resistant *Helicobacter pylori* infection?

Brennan DE, Dowd C, O'Morain C, McNamara D, Smith SM

- 982 Dysregulation of PARP1 is involved in development of Barrett's esophagus

Zhang C, Ma T, Luo T, Li A, Gao X, Wang ZG, Li F

- 992 Autophagy activation by Jiang Zhi Granule protects against metabolic stress-induced hepatocyte injury

Zheng YY, Wang M, Shu XB, Zheng PY, Ji G

- 1004 Long noncoding RNA RP4 functions as a competing endogenous RNA through miR-7-5p sponge activity in colorectal cancer

Liu ML, Zhang Q, Yuan X, Jin L, Wang LL, Fang TT, Wang WB

Retrospective Study

- 1013 Quality indicators in pediatric colonoscopy in a low-volume center: Implications for training

Lee WS, Tee CW, Koay ZL, Wong TS, Zahraq F, Foo HW, Ong SY, Wong SY, Ng RT

- 1022 Prognostic value of lymph nodes count on survival of patients with distal cholangiocarcinomas

Lin HP, Li SW, Liu Y, Zhou SJ

Clinical Practice Study

- 1035 Phenotypic and genotypic characterization of inflammatory bowel disease in children under six years of age in China

Fang YH, Luo YY, Yu JD, Lou JG, Chen J

Randomized Controlled Trial

- 1046 Effect of polyglycolic acid sheet plus esophageal stent placement in preventing esophageal stricture after endoscopic submucosal dissection in patients with early-stage esophageal cancer: A randomized, controlled trial

Chai NL, Feng J, Li LS, Liu SZ, Du C, Zhang Q, Linghu EQ

CASE REPORT

- 1056** Four cancer cases after esophageal atresia repair: Time to start screening the upper gastrointestinal tract

Vergouwe FW, Gottrand M, Wijnhoven BP, IJsselstijn H, Piessen G, Bruno MJ, Wijnen RM, Spaander MC

ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, Sang Chul Lee, MD, PhD, Chief Doctor, Full Professor, Professor, Surgeon, Surgical Oncologist, Division of Colorectal Surgery, Department of General Surgery, Catholic University of Korea, Daejeon St. Mary's Hospital, Daejeon 34943, South Korea

AIMS AND SCOPE

World Journal of Gastroenterology (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7th, 14th, 21st, and 28th each month. The *WJG* Editorial Board consists of 642 experts in gastroenterology and hepatology from 59 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

INDEXING/ABSTRACTING

World Journal of Gastroenterology (*WJG*) is now indexed in Current Contents[®]/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch[®]), Journal Citation Reports[®], Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2017 edition of Journal Citation Reports[®] cites the 2016 impact factor for *WJG* as 3.365 (5-year impact factor: 3.176), ranking *WJG* as 29th among 79 journals in gastroenterology and hepatology (quartile in category Q2).

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: Xiang Li
Responsible Electronic Editor: Yan Huang
Proofing Editor-in-Chief: Lian-Sheng Ma

Responsible Science Editor: Ze-Mao Gong
Proofing Editorial Office Director: Jin-Lei Wang

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
ISSN 1007-9327 (print)
ISSN 2219-2840 (online)

LAUNCH DATE
October 1, 1995

FREQUENCY
Weekly

EDITORS-IN-CHIEF
Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

Stephen C Strom, PhD, Professor, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

EDITORIAL BOARD MEMBERS
All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

EDITORIAL OFFICE
Ze-Mao Gong, Director
World Journal of Gastroenterology
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLISHER
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLICATION DATE
March 7, 2018

COPYRIGHT
© 2018 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS
Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION
<http://www.f6publishing.com>

Quantitative and noninvasive assessment of chronic liver diseases using two-dimensional shear wave elastography

Li-Ting Xie, Chun-Hong Yan, Qi-Yu Zhao, Meng-Na He, Tian-An Jiang

Li-Ting Xie, Chun-Hong Yan, Qi-Yu Zhao, Meng-Na He, Tian-An Jiang, Department of Ultrasound, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China

ORCID number: Li-Ting Xie (0000-0002-0498-193X); Chun-Hong Yan (0000-0001-8084-4155); Qi-Yu Zhao (0000-0002-8732-8564); Meng-Na He (0000-0002-8178-3531); Tian-An Jiang (0000-0002-7672-8394).

Author contributions: Xie LT, Yan CH, Zhao QY, He MN and Jiang TA contributed to the research, and to drafting and editing of the manuscript; all authors approved the final draft submitted.

Conflict-of-interest statement: Authors declare no conflict of interests for this article.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Correspondence to: Tian-An Jiang, MD, PhD, Professor, Surgeon, Department of Ultrasound, The First Affiliated Hospital, College of Medicine, Zhejiang University, Qingchun Road, No.79, Hangzhou 310003, Zhejiang Province, China. tiananjiang@zju.edu.cn
Telephone: +86-18857127666

Received: December 28, 2017

Peer-review started: December 29, 2017

First decision: January 17, 2018

Revised: February 1, 2018

Accepted: February 9, 2018

Article in press: February 9, 2018

Published online: March 7, 2018

Abstract

Two-dimensional shear wave elastography (2D-SWE) is a rapid, simple and novel noninvasive method that has been proposed for assessing hepatic fibrosis in patients with chronic liver diseases (CLDs) based on measurements of liver stiffness. 2D-SWE can be performed easily at the bedside or in an outpatient clinic and yields immediate results with good reproducibility. Furthermore, 2D-SWE was an efficient method for evaluating liver fibrosis in small to moderately sized clinical trials. However, the quality criteria for the staging of liver fibrosis are not yet well defined. Liver fibrosis is the main pathological basis of liver stiffness and a key step in the progression from CLD to cirrhosis; thus, the management of CLD largely depends on the extent and progression of liver fibrosis. 2D-SWE appears to be an excellent tool for the early detection of cirrhosis and may have prognostic value in this context. Because 2D-SWE has high patient acceptance, it could be useful for monitoring fibrosis progression and regression in individual cases. However, multicenter data are needed to support its use. This study reviews the current status and future perspectives of 2D-SWE for assessments of liver fibrosis and discusses the technical advantages and limitations that impact its effective and rational clinical use.

Key words: Elastography; Shear wave; Chronic liver disease; Liver fibrosis

© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: There has been considerable research in recent years dedicated to the development of noninvasive methods of chronic liver diseases (CLDs). These include novel elastography methods. In this review, we outline the current state and future perspectives of the commonly used two-dimensional

shear wave elastography (2D-SWE) in CLDs. In particular, we discuss the applications and problems in chronic viral hepatitis, nonalcoholic fatty liver disease, alcoholic liver disease, liver transplantation, focal liver lesions, and autoimmune liver disease to synthesize existing evidence for the reader. This is the first full and complete review to assess various CLDs using 2D-SWE.

Xie LT, Yan CH, Zhao QY, He MN, Jiang TA. Quantitative and noninvasive assessment of chronic liver diseases using two-dimensional shear wave elastography. *World J Gastroenterol* 2018; 24(9): 957-970 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v24/i9/957.htm> DOI: <http://dx.doi.org/10.3748/wjg.v24.i9.957>

INTRODUCTION

Liver fibrosis results from repetitive or sustained liver inflammation caused by chronic liver diseases (CLDs) and has serious long-term consequences in terms of patient morbidity and mortality due to the progression to cirrhosis. Patients with cirrhosis are at a higher risk of developing complications, including esophageal varices, ascites, liver failure and hepatocellular carcinoma (HCC), than healthy individuals^[1,2]. Liver fibrosis is an important factor in the development of various CLDs and is mainly mediated by chronic liver injury, which leads to liver fibrosis characterized by increased extracellular matrix production by fibroblast-like cells and increased liver stiffness (LS)^[3]. The precise assessment of the severity of liver fibrosis and reliable diagnosis of cirrhosis are vital steps in the management of CLDs, as they provide information that impacts therapeutic decisions^[4,5].

Liver biopsy remains the reference standard for the staging of liver fibrosis, despite its limitations, including its invasivity and the pain experienced by patients, high cost, risk of bleeding and poor reproducibility, and contraindications, such as cases of massive ascites^[6,7]. Furthermore, the accuracy of liver biopsy is influenced by several factors, including intra- and interobserver variability and sampling error^[8,9]. Given these limitations, liver biopsy is not an ideal method for repeated assessments of disease progression as well.

The noninvasive assessment of liver fibrosis has recently become a research focus, leading to the introduction of new technologies. In particular, shear wave elastography (SWE), which is based on ultrasound (US) technology, has been widely applied and has gained acceptance. The latest guidelines on the clinical use of liver US elastography of the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB)^[10] and the guidelines on the evaluation of liver disease severity and prognosis of the European Association for the Study of the Liver- Asociación Latinoamericana para el Estudio del Hígado state that two-dimension (2D)-SWE is a valid and promising

technique for noninvasive staging of liver fibrosis in viral hepatitis and seems to be at least equivalent to transient elastography (TE) and point SWE (pSWE)/acoustic radiation force impulse (ARFI)^[11].

BASICS OF 2D-SWE

Comparison of elastography methods

Several elasticity imaging techniques have recently been developed for assessing the mechanical properties of liver tissues and staging the fibrosis level using different imaging modalities. In accordance with the Guidelines for the Basic Principles and Technology of EFSUMB^[12], the available US-based elastography techniques include strain elastography (SE) and SWE; SWE can be further subdivided into three techniques - TE, pSWE and 2D-SWE - in addition to radiology-based magnetic resonance elastography (MRE).

Among these, TE is the most widely used elastography method. However, in a study of 13369 CLD patients over a 5-year period of using TE, unreliable results were obtained in 15.8% of cases^[13]. The limitations of TE, such as the difficulty in measuring obese patients and patients with narrow intercostal spaces, the variations in operator experience, and the fact that it is not applicable in patients with ascites, were the primary factors contributing to these unreliable results. Importantly, the issue of obesity has been partially addressed by the introduction of specially designed XL probes that measure LS deeper than the standard M probes. It has also been reported that TE and ARFI elastography are inaccurate in the detection of early and intermediate fibrosis^[14,15].

MRE can be used to quantitatively diagnose liver fibrosis with high accuracy and is mainly used for the diagnosis of advanced liver fibrosis and cirrhosis. The diagnostic accuracy of MRE increased when the liver fibrosis was getting serious, whereas the level of early fibrosis detected by MRE is inaccurate^[16,17]. 2D-SWE is the latest elastography technology and can assess the elasticity of liver tissue easily and quickly, thus reflecting the degree of liver fibrosis. Table 1 demonstrates the comparison of currently available noninvasive methods in patients with CLD.

Principles of 2D-SWE

2D-SWE is a novel noninvasive method that has been proposed for assessing LS by measuring the velocity of elastic shear waves in the liver parenchyma^[18]. In SWE, shear waves are created by US-generated pulses of an acoustic radiation force (Figure 1). The velocity of the shear wave is then estimated by a Doppler-like effect over a region of interest (ROI) and is related to the stiffness or elasticity of the medium^[19]. This shear wave velocity can be used to calculate the tissue stiffness by the formula $E = \rho c^2$, where E is tissue elasticity (Young's modulus, kPa), ρ is tissue density (kg/m^3), and c is shear wave velocity (m/s)^[20,21].

Table 1 Comparison of currently available noninvasive methods in patients with chronic liver disease

Content	Methods			
	TE	pSWE	2D-SWE	MRE
Technical principle	TE was the first commercially available elastography method developed for measuring liver stiffness using a dedicated device that includes an amplitude modulation (A) mode image for organ localization	pSWE can be implemented on a common ultrasound diagnostic system. It uses a regular ultrasonic probe to emit a single impulse of acoustic radiation force and generates a shear wave to detect the shear wave propagation velocity	2D-SWE is the combination of a radiation force applied to the tissues by focused ultrasonic beams and a very high frame rate US imaging sequence, which is able to capture the propagation of resulting the shear waves in real time	MRE enables the measurement of liver stiffness with an MRI-compatible generator; mechanical shear waves are delivered to the tissue and displayed as elastograms using phase-contrast image sequences
Reference point	•Young's modulus (kPa)	•Shear wave speed (m/s) •Young's modulus (kPa)	•Shear wave speed (m/s) •Young's modulus (kPa)	•Shear wave speed (m/s) •Young's modulus (kPa)
Selected example	•FibroScan (Echosens, France)	•VTQ using ARFI imaging (Siemens Healthcare, Germany) •ElastPQ (Philips Healthcare, Netherlands) •Shear Wave Measurement (Hitachi Aloka Medical, Japan)	•SWE (SuperSonic Imagine, France) •Virtual Touch IQ (Siemens Healthcare, Germany) •Logiq E9 (GE Healthcare, United Kingdom) •Aplio 500 (Toshiba Medical Systems, United Kingdom)	•MR Touch (GE Healthcare, United Kingdom) •MRE (Philips Healthcare, Netherlands; Siemens Healthcare, Germany)
Advantages	<ul style="list-style-type: none"> •Most widely used and validated technique •Quality criteria well defined •User friendly, rapid, easy to measure at the bedside •Good reproducibility •Good performance for noninvasive assessments of liver fibrosis staging •Excellent diagnostic accuracy for excluding liver cirrhosis •Prognostic value in cirrhosis 	<ul style="list-style-type: none"> •Can be performed using a regular US machine •The ROI can be positioned under B-mode visualization •Higher applicability than TE (not limited by ascites or obesity) •pSWE is equal to the performance of TE for significant fibrosis and cirrhosis 	<ul style="list-style-type: none"> •Can be performed using a regular US machine •Simple and fast to use •The ROI can be positioned under B-mode visualization •A larger ROI than that of TE and pSWE •Good applicability (not limited by ascites or obesity) •Good stability and reproducibility •Generates a real-time quantitative map of liver tissue stiffness •Can avoid large vessels and the gallbladder •High performance for cirrhosis 	<ul style="list-style-type: none"> •Can be performed using a regular MRI machine •Good stability and reproducibility •Scans the whole liver •Higher applicability than TE (not limited by ascites or obesity) •Excellent diagnostic accuracy for noninvasive staging of liver fibrosis and cirrhosis
Disadvantages	<ul style="list-style-type: none"> •Requires a special device and probe •ROI size is rather small and cannot be chosen •Lack of applicability (limited by ascites, severe obesity) •No B-mode orientation •Cannot avoid large vessels or the gallbladder •Unable to distinguish between intermediate stages of liver fibrosis 	<ul style="list-style-type: none"> •ROI size is smaller than that of TE and cannot be modified •Quality criteria not yet well defined •Narrow range of values •Unable to distinguish between intermediate stages of liver fibrosis 	<ul style="list-style-type: none"> •Quality criteria not well defined •No further prospective studies published •Many factors cause failed measurements in clinical practice •Unable to distinguish between intermediate stages of liver fibrosis 	<ul style="list-style-type: none"> •Time-consuming •Even more costly than SWE and TE •Failure can occur due to claustrophobia and iron overload •Affected by respiratory movement •Hepatic MRE signal may be so low that waves cannot be adequately visualized with a gradient-echo based MRE sequence

2D-SWE: Two-dimensional shear wave elastography; MRE: Magnetic resonance elastography; MRI: Magnetic resonance imaging; pSWE: Point shear wave elastography; ROI: Region of interest; TE: Transient elastography; US: Ultrasound; VTQ: Virtual touch tissue quantification.

Elasticity is shown on a color-coded image displayed on a B-mode image. Then, with the ROI on the elasticity image, the mean, maximal and minimal LS values within the ROI can be visualized on a screen, along with the standard deviation (SD) of the measured elasticity^[19,22]. The size and position of the ROI can be modified by the operator based on the specific goals of each liver assessment (Figure 2). In general, red areas indicate larger Young's modulus of stiffer tissues, while blue areas indicate smaller Young's modulus of softer tissues.


Examination technique

2D-SWE examination of the liver is performed by using convex US probes with integrated technological solutions allowing elasticity imaging and measurements, according to the World Federation for Ultrasound in Medicine and Biology^[22,23] and the EFSUMB Guidelines for the Clinical Use of US Elastography^[10,12], as well as the Society of Radiologists in Ultrasound Consensus Conference Statement regarding the assessment of liver fibrosis by elastography^[24]. The proper examination procedure is described in Table 2, and the precautions

Table 2 Procedures of two-dimensional shear wave elastography

Key points	Procedures
Adequate preparation	<ul style="list-style-type: none"> Fast and rest before the exam Perform in a supine position Train the patients on breathing
Accurate positioning	<ul style="list-style-type: none"> Scan the 6/7/8 intercostal spaces of the right liver Acquire stable and high-quality images Instruct the patient to hold the breath for 3-5 s
Stable measurement	<ul style="list-style-type: none"> Switch to SWE mode Freeze the image and adjust the position of the ROI Calculate the LS automatically Average the repeated measurement values

LS: Liver stiffness; ROI: Region of interest; SWE: Shear wave elastography.



Acoustic radiation force

Figure 1 The principle of two-dimensional shear wave elastography. 2D-SWE is created by ultrasound-generated pulses from an acoustic radiation force that produce plane shear waves, and the propagation of the resulting shear waves can be captured in real time. 2D-SWE: Two-dimensional shear wave elastography.

and techniques of 2D-SWE in Table 3.

Normal value

"Normal" LS values have recently been studied in healthy subjects who have undergone a professional check-up and who have no overt causes of liver disease, with normal liver enzymes. Various results for normal LS values are shown in Table 4.

CLINICAL APPLICATIONS OF 2D-SWE

Diagnosis of chronic viral hepatitis

Viral hepatitis is a global public health issue, with approximately 248 million and 185 million people worldwide suffering from chronic hepatitis B (CHB) and hepatitis C (CHC), respectively^[25-27]. Patients with advanced liver fibrosis from chronic viral hepatitis have a high risk of developing liver cancer and related complications, including portal hypertension (PH), esophageal and gastric variceal bleeding (EGVB), and liver failure. In these cases, prognosis and treatment are mainly affected by the degree of fibrosis, and the primary aim of treatment is controlling the progression

of liver fibrosis^[28,29]. The clinical practice guidelines for the management of CHB and CHC of the European Association for the Study of the Liver (EASL)^[30,31], as well as the World Health Organization Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection^[32], recommend elastography as a routine method for clinically evaluating liver fibrosis to avoid the need for liver biopsy in some patients.

Recent studies performed worldwide have focused on 2D-SWE for determining the role of viral hepatitis in liver fibrosis. In one study, 454 CHB patients were examined by 2D-SWE and TE^[33]. The results showed that 2D-SWE provided a more accurate correlation of liver elasticity with liver fibrosis stage than TE, especially for the identification of significant fibrosis ($\geq F2$). Bavu *et al*^[18] examined 113 CHC patients and found that SWE performed better diagnostically for early, intermediate and advanced predicted levels of fibrosis than TE. Ferraioli *et al*^[20] used biopsy as a reference to assess the accuracy of SWE and TE in 121 CHC patients; they found that real-time SWE was more accurate than TE for assessing significant fibrosis ($\geq F2$). These results were strongly supported by three meta-analyses published by other authors^[34-36]. In addition, a recent large-sample meta-analysis concluded that SWE was more accurate for advanced fibrosis ($\geq F3$) and cirrhosis (F4)^[37]. What's more, Grgurevic *et al*^[38] evaluated the performance of real-time 2D-SWE for quantitatively assessing liver and spleen stiffness in patients with chronic viral hepatitis. They showed that real-time 2D-SWE can accurately identify various degrees of liver fibrosis and cirrhosis and demonstrated that liver and spleen stiffness continue to increase even after cirrhosis has developed. In fact, they noticed that spleen and liver stiffness tended to converge in more advanced stages of liver cirrhosis. This is an important study showing that 2D-SWE can be used to study the evolution of liver disease beyond cirrhosis.

As described above, SWE has high accuracy and specificity for assessing liver fibrosis due to chronic viral hepatitis, which makes it convenient for the real-time clinical monitoring of liver fibrosis. SWE technology is expected to replace biopsy, thereby eliminating the invasiveness and poor reproducibility of the latter technique. However, the quality criteria for the staging of liver fibrosis are not yet well defined. In addition, 2D-SWE has shown different diagnostic accuracies for liver fibrosis in patients with CHB and CHC. We suppose that this is probably due to the different etiologies of hepatitis B virus (HBV) and hepatitis C virus that lead to different tissue patterns and distributions of fibrosis development. Specifically, cirrhosis patients with HBV tend to produce larger regenerative nodules, which may result in different LS measurements if the ROI is placed in such an area. These findings suggest that assessments of the degree of liver fibrosis in different liver diseases cannot be based on the same diagnostic criteria, leading to

Table 3 Precautions and techniques of two-dimensional shear wave elastography

Key points	Precautions and techniques
Fasting and resting	<ul style="list-style-type: none"> Patients should fast for a minimum of 2 h and rest for a minimum of 10 min before undergoing liver stiffness measurement with SWE
Position	<ul style="list-style-type: none"> Measurement of liver stiffness by 2D-SWE should be performed in a supine position with the right arm maximally extended; this position ensures the best possible access for assessing the right liver lobe The transducer is placed in a right intercostal space to visualize the right liver lobe in B mode
Breathing train	<ul style="list-style-type: none"> Instruct the patient not to breathe in or breathe out deeply in order to eliminate unreliable measurements induced by breathing movements It has been suggested that a breath hold for a few seconds during quiet breathing may lead to the best results
Clear 2D-US images	<ul style="list-style-type: none"> Adequate B-mode liver image is a prerequisite for 2D-SWE measurements Must avoid the ribs, gas and other factors of routine ultrasound The appropriate pressure can be applied with the ultrasound probe to broaden the intercostal space and, thus, acquiring clear images. Contrary to the ordinary suggestion, this does not increase the liver's stiffness, as the intervening tissues prevent distortion of the liver surface
Scale	<ul style="list-style-type: none"> Generally, the Young's modulus scale should not be less than 30 kPa and preferably not higher than 150 kPa
Depth	<ul style="list-style-type: none"> Liver stiffness measured by 2D-SWE should be performed at least 10 mm under the liver capsule Measurements should not be performed too deep or too close, in order to avoid reverberation artifacts, insufficient penetration and acoustic shadow, as these factors will lead to incorrect results
Sampling frame	<ul style="list-style-type: none"> The sampling frame should be placed in a well-visualized area of the right liver lobe, free of large vessels, the gallbladder, the liver capsule, and any other hollow organs In addition, the sampling frame should be placed in the center of the image
ROI	<ul style="list-style-type: none"> For valid measurement quality of 2D-SWE, the ROI should be placed at a minimum of 1-2 cm and a maximum of 6 cm beneath the liver capsule The SWE acquisition is continued for 4-5 s once a stable SWE image is obtained The operator freezes the image, and the ROI should be placed in the most homogeneously colored area of the SWE ROI
Penetration mode	<ul style="list-style-type: none"> When measuring patients with thick subcutaneous fat, fatty liver or advanced cirrhosis, SWE can be adjusted to "Pen" mode to improve the measurement success rate In 2D-SWE, if the signal is weak or unstable, the penetration mode can be activated

2D-SWE: Two-dimensional shear wave elastography; 2D-US: Two-dimensional ultrasound; Pen: Penetration; ROI: Region of interest; SWE: Shear wave elastography.




Figure 2 Example of two-dimensional shear wave elastography of the liver implemented using the Aixplorer US system (SuperSonic Imaging, France), which can be displayed simultaneously with the B-mode image. A 2D-SWE image from a 42-year-old male who had normal liver function with liver biopsy-proven fibrosis at METAVIR stage F0. The rectangular box is the area of view where the shear wave measurements were made and color-coded. The round circle is the ROI where the measurements were obtained. The system provides the mean, Max, Min, SD and Diam of the stiffness measurements within the ROI. For this case, the following measurements were made: Young's modulus: Mean = 4.8 kPa, Min = 3.3 kPa, Max = 5.8 kPa, SD = 0.4 kPa; shear wave velocity: Mean = 1.3 m/s, Min = 1.1 m/s, Max = 1.4 m/s, SD = 0.1 m/s, Depth = 3.6 cm, and Diam = 15.0 mm. 2D-SWE: Two-dimensional shear wave elastography; Diam: Diameter; Max: Maximum; Min: Minimum; ROI: Region of interest; SD: Standard deviation; US: Ultrasound.

the issue of how to establish diagnostic criteria for patients with multiple CLDs, *e.g.*, HBV patients with nonalcoholic fatty liver disease (NAFLD).

In the future, diagnosis and treatment in such situations will require personalization. The lack of specific criteria may also be due to the paucity of studies, small sample sizes, and diverse research areas; future developments will require more evidence-based medical data from large-scale, multicenter studies. Table 5 includes the cut-off values of LS assessed by 2D-SWE in various studies. Figure 3 shows 2D-SWE of liver fibrosis at METAVIR stages F1 through F4. Note that the LS gradually increases, and the color of the sampling frame gradually changes in the initial stages and incrementally increases in the later stages of fibrosis.

Diagnosis of NAFLD

NAFLD is the most prevalent CLD, representing a spectrum ranging from simple fatty liver (SFL) to nonalcoholic steatohepatitis (NASH)^[39,40]. NAFLD has become a global health problem, with a prevalence comparable to the rates of metabolic syndrome, obesity, type 2 diabetes mellitus and dyslipidemia^[41,42]. The morbidity and mortality of patients with NAFLD are related to the development of NASH, which may progress to fibrosis and cirrhosis, even resulting in an increased risk of HCC^[43]. A meta-analysis^[44] demonstrated that even SFL may result in fibrosis development, and fibrosis development was observed in approximately 30% of patients with SFL, as well as in patients with NASH. Liver fibrosis, but no other histological features, has been demonstrated as the

Table 4 Summary of the literature for two-dimensional shear wave elastography normal values

Ref.	Year	Country	Number	Mean age	Sex, female/ male	Mean SWE, standard deviation, range	Remarks
Muller <i>et al</i> ^[19]	2009	France	15	NA	NA	2.6-6.2 kPa	No data available regarding age or sex of normal subjects
Ferraioli <i>et al</i> ^[79]	2012	Italy	42	34.8	13/29	4.92-5.39 kPa	
Sirli <i>et al</i> ^[82]	2013	Romania	82	26	56/26	6.0 ± 1.4 kPa	Female: 5.7 ± 1.3 kPa Male: 6.6 ± 1.5 kPa BMI ≥ 25 kg/m ² : 6.5 ± 1.5 kPa BMI < 25 kg/m ² : 5.8 ± 1.3 kPa
Hudson <i>et al</i> ^[83]	2013	Canada	15	27	5/10	5.55 ± 0.74 kPa	
Wang <i>et al</i> ^[84]	2014	China	30	36.1 ± 14.7	14/16	4.29 kPa	
Suh <i>et al</i> ^[73]	2014	South Korea	196	29.2 ± 9.2	66/130	2.6-6.2 kPa	
Huang <i>et al</i> ^[85]	2014	China	502	37.9	310/192	5.10 ± 1.02 kPa	Female: 5.45 ± 1.02 kPa Male: 4.89 ± 0.96 kPa
Yoon <i>et al</i> ^[86]	2014	South Korea	122	NA	NA	5.12 ± 1.46 kPa (session I) 4.95 ± 1.40 kPa (session II)	No data available regarding age or sex of normal subjects
Leung <i>et al</i> ^[33]	2013	China	171	40.6 ± 10.8	103/68	5.5 ± 0.7 kPa	Female: 5.7 ± 0.5 kPa Male: 5.4 ± 0.7 kPa
Franchi-Abella <i>et al</i> ^[87]	2016	France	51	0-15	26/25	6.53 ± 1.38 kPa	No significant differences were observed between male and female patients, right and left lobes, or different breathing conditions

NA: Not available.




Figure 3 Two-dimensional shear wave elastography (Aixplorer US system, SuperSonic Imaging, France) of the liver in chronic hepatitis B patients with liver biopsy-proven fibrosis at METAVIR stages F1 through F4. A: F1 stage, mean Young's modulus = 5.1 kPa, mean shear wave velocity = 1.3 m/s; B: F2 stage, mean Young's modulus = 7.4 kPa, mean shear wave velocity = 1.4 m/s; C: F3 stage, mean Young's modulus = 8.7 kPa, mean shear wave velocity = 1.7 m/s; D: F4 stage, mean Young's modulus = 11.4 kPa, mean shear wave velocity = 1.9 m/s. Note the liver stiffness gradually increases, and the color of the sampling frame gradually changes in the initial stages and incrementally increases in the later stages of fibrosis. 2D-SWE: Two-dimensional shear wave elastography; US: Ultrasound.

single most crucial histological feature associated with the risk of liver-related complications and death in patients with NAFLD^[45]. Therefore, the most important

issue for patients with NAFLD is recognizing and assessing the stage of liver fibrosis, which is possible by using US elastography.

Table 5 Cut-off values of liver stiffness assessed with two-dimensional shear wave elastography in various studies

Ref.	Etiologies	Year	Country	Patients, n	≥ F1 (fibrosis)			≥ F2 (significant fibrosis)			≥ F3 (severe fibrosis)			F4 (cirrhosis)		
					Cut-off, kPa	AUROC, %		Cut-off, kPa	AUROC, %		Cut-off, kPa	AUROC, %		Cut-off, kPa	AUROC, %	
Leung <i>et al.</i> ^[31]	HBV	2013	China	454	6.5	86	7.1	88	7.9	93	10.1	98		10.1	98	
Herrmann <i>et al.</i> ^[37]	HBV	2017	Germany	206	NA	NA	7.1	91	8.1	91	11.5	96		11.5	96	
Zeng <i>et al.</i> ^[29]	HBV	2014	China	303	NA	NA	7.2	92	9.7	95	11.7	95		11.7	95	
Bavu <i>et al.</i> ^[38]	HCV	2011	France	113	NA	NA	9.1	95	10.1	96	13.3	97		13.3	97	
Ferraioli <i>et al.</i> ^[20]	HCV	2012	Italy	121	NA	NA	7.1	92	8.7	98	10.4	98		10.4	98	
Grigorevic <i>et al.</i> ^[38]	CVH	2015	Croatia	123	NA	NA	8.1	99	NA	NA	10.8	95		10.8	95	
Cassinotto <i>et al.</i> ^[46]	NAFLD	2014	France	108	NA	NA	6.3	86	8.3	89	10.5	88		10.5	88	
Garcovich <i>et al.</i> ^[47]	NAFLD	2016	Italy	78	5.1	92	6.7	96	NA	NA	NA	NA		NA	NA	
Thiele <i>et al.</i> ^[51]	ALD	2016	Denmark	199	NA	NA	10.2	94	NA	NA	16.4	95		16.4	95	

2D-SWE: Two-dimensional shear wave elastography; ALD: Alcoholic liver disease; AUROC: Area under the receiver operating characteristic curve; CVH: Chronic viral hepatitis; HBV: Hepatitis B virus; HCV: Hepatitis C virus; LS: Liver stiffness; NA: Not available; NAFLD: Nonalcoholic fatty liver disease.

Cassinotto *et al.*^[46] enrolled 291 patients with NAFLD and compared the performance of 2D-SWE, TE and Virtual Touch Quantification using liver biopsy as the reference method. They found that although obesity was related to an increased rate of failed LS measurements, these techniques, especially SWE, were valuable for diagnosing liver fibrosis in patients with NAFLD. The diagnostic performances of 2D-SWE for assessing liver fibrosis are as follows. For a sensitivity of at least 90% for diagnosing significant fibrosis ($\geq F2$), severe fibrosis ($\geq F3$) and cirrhosis (F4), the specificity is approximately 60%-70%; for a specificity of at least 90%, the sensitivity is approximately 50%-70%. 2D-SWE had areas under the receiver operating characteristic curves of 86%, 89% and 88% for the diagnosis of $\geq F2$, $\geq F3$ and F4, respectively. Furthermore, LS was mainly related to the fibrosis stage, and steatosis, inflammation and hepatocyte ballooning did not have significant influences on LS. Some NASH patients may have no fibrosis, and SWE may not be useful for the diagnosis of early-stage NASH without fibrosis. Hence, the next question became whether SWE can differentiate NASH from SFL, especially in the early stages of fibrosis. Probably not, and this is an area that relies on biochemical methods. Solutions to these problems will require multifaceted, prospective clinical studies to establish cut-off values for fibrosis staging.

In a study using SWE to identify the diagnostic accuracy of different degrees of fibrosis in 78 pediatric patients with biopsy-proven NASH^[47], SWE was shown to be able to accurately evaluate significant liver fibrosis and, less efficiently, mild liver fibrosis in pediatric NAFLD patients. The study suggested that SWE can be used to assess liver fibrosis not only in adults but also in children and adolescents. However, few studies have focused on children; although fibrosis can be detected in children, the stage of fibrosis cannot yet be fully resolved, especially for fibrosis due to fatty liver. Consequently, the technique should be extended to all ages to further demonstrate the stability and reliability of the results.

Diagnosis of alcoholic liver disease

Alcoholic liver disease (ALD) is the most common liver disease in the Western world. Chronic and excessive alcohol consumption is responsible for the progression of alcoholic steatosis, hepatitis, fibrosis and cirrhosis. Complete therapy requires abstinence from alcohol. Moreover, liver transplantation (LT) remains a life-saving treatment for patients with advanced ALD^[48,49]. The EASL published clinical practice guidelines for the management of ALD in 2012^[50]. The guidelines noted that elastography is a notable method for the early diagnosis of alcoholic cirrhosis.

A recent prospective study of 199 alcohol-overusing individuals with varying degrees of alcoholic liver fibrosis evaluated two elastography methods for the diagnosis of alcoholic fibrosis and cirrhosis, using liver biopsy as a reference^[51]. The study found that 2D-SWE has a high accuracy (area under the curve ≥ 0.92) for identifying subjects with significant fibrosis and cirrhosis, and the 2D-SWE cut-off values for optimal identification of significant fibrosis and cirrhosis were 10.2 kPa and 16.4 kPa. 2D-SWE was an extremely useful tool for diagnosing alcoholic fibrosis and, furthermore, was more appropriate for diagnosing early cirrhosis than for distinguishing

between early and advanced cirrhosis. However, the threshold values that will allow the accurate diagnosis of cirrhosis by SWE and obviate the need for liver biopsy in adults with ALD remain to be determined.

Patients with advanced ALD ultimately experience life-threatening complications, such as PH and ascites. These may lead to EGVB, which is among the most important causes of high mortality in patients with cirrhosis^[52]. Therefore, assessing the severity of PH during follow-up is essential in patients with cirrhosis. The hepatic venous pressure gradient (HVPG) has been used to assess PH, but it is rarely used in clinical practice because of its invasiveness. A recent study found that LS measured by SWE is an independent predictor of the presence of HCC and esophageal and gastric varices in patients with CLD^[53]. Another study demonstrated that SWE, as a promising tool to diagnose PH, has outstanding diagnostic accuracy, with a specificity and sensitivity ranging around 80%, and showed it to be superior to TE^[54]; however, more than 30% of the clinically significant PH patients could not be conclusively diagnosed or ruled disease-free because their SWE values were between the cut-offs. Several recent studies have reported that LS measured by SWE in connection with HVPG is important for predicting clinically significant PH in patients with cirrhosis^[55,56]. Thus, although 2D-SWE has exceptional clinical value for assessing HCC patients with PH and EGVB, it still cannot replace digestive endoscopy^[52].

Assessment of end-stage liver disease after LT

LT is the only therapy for many patients who eventually progress to end-stage liver disease. However, LT is associated with a high rate of complications, which are difficult to identify in the early stages. One study reported a right lobe liver transplant recipient who experienced anastomotic stenosis of the right hepatic vein. SWE was quantitatively used to evaluate stiffness. The results suggested that SWE may be a noninvasive tool for assessing alterations in LS secondary to hepatic venous congestion after LT^[57]. Another study showed that SWE may be useful during follow-up after LT. Liver rejection or hepatitis can be predicted at > 4 wk based on liver grafts that are stiffer than normal^[58]. In a more recent study, SWE was successfully utilized to monitor the therapeutic effects of direct-acting antivirals in hepatitis C recurrence after LT; the median LS values decreased dramatically after treatment ($P < 0.001$). The study suggested that SWE is a valid diagnostic tool to follow-up hepatitis C patients undergoing LT^[59].

From this study, we observed that SWE aids in the clinical diagnosis and detection of complications after LT, which represents great progress in SWE technology from diagnosis to monitoring. However, few studies have examined elastography in LT. This study represents the first step, although there is great potential for future research opportunities. Moreover, US elastography should be applied more for monitoring

and predicting the complications of LT, particularly for assessing disease progression and prognosis.

Assessment of focal liver lesions

Focal liver lesions (FLLs) represent novel lesions for the field of US elastography and include those found in hemangioma, HCC, focal nodular hyperplasia (FNH), metastatic cancer and adenoma. Several studies have reported that 2D-SWE is a useful method for distinguishing FLLs, although it does not completely distinguish benign from malignant lesions^[60-64]. The stiffness of lesions in liver malignancies is significantly higher than that of the liver parenchyma and is also higher than that of benign lesions^[60,61] (Figure 4 shows HCC images of 2D-SWE). In malignant tumors, the hardness values of metastases were significantly higher than those found in HCC and cholangiocarcinoma^[62]. In benign lesions, 2D-SWE has been regarded as a practical tool for distinguishing FNH from adenoma^[63].

A recent study demonstrated the correct differentiation between benign and malignant FLLs by using real-time 2D-SWE in 96.1% of patients (area under the curve = 0.98)^[64]. They used three elastography parameters, the mean stiffness of the FLL, the ratio between the minimal and maximum lesion stiffness, and the ratio between the stiffness of the FLL and the surrounding liver parenchyma to construct a new Liver Elastography Malignancy Prediction score based on a regression analysis. A simpler approach considering only mean lesion stiffness in a dichotomized fashion could be used to diagnose or rule-out malignancy with cut-off values of 14 kPa and 32.5 kPa, respectively.

Nonetheless, conclusions based on the current literature remain unclear. When 2D US and Doppler US suggest that a lesion is a benign tumor but elastography suggests malignancy, the lesion cannot therefore be diagnosed as malignant. Several technical limitations still exist. In situations in which the lesion is smaller than the ROI or located deep or near the heart, the shear wave propagation and imaging stability will be affected. Furthermore, lesion areas with necrotic liquefaction or calcification are not representative of the true lesion stiffness, which often leads to misdiagnosis.

Assessment of autoimmune liver disease

Autoimmune liver disease (AILDs) are intricate disorders resulting from the effects of multiple genes in association with environmental factors. The three major AILDs are primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis^[65]. As they progress, these diseases may ultimately lead to chronic liver damage, liver fibrosis and cirrhosis. Zeng *et al*^[66] used liver biopsy as the reference standard for determining the diagnostic accuracy of 2D-SWE for noninvasively assessing liver fibrosis in patients with AILD. Their results indicated that the optimal cut-off values for significant fibrosis ($\geq F2$), severe fibrosis ($\geq F3$) and cirrhosis (F4) were 9.7




Figure 4 Two-dimensional shear wave elastography (Aixplorer US system, SuperSonic Imaging, France) images of a 69-year-old male with hepatocellular carcinoma based on the cirrhosis caused by hepatitis B virus. A: The mean Young's modulus is 161.8 kPa and the mean shear wave velocity is 7.3 m/s, which is obviously higher than the benign lesion; B: The area of the tumor is 13.03 cm². 2D-SWE: Two-dimensional shear wave elastography; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; US: Ultrasound.

kPa, 13.2 kPa and 16.3 kPa, respectively. Moreover, the sensitivity and specificity ranged from 75% to 87% for all fibrosis stages. As these data show, SWE has high cut-off values in patients with AILD. The critical cut-off value was obviously higher than that for CHB/CHC. Therefore, different diseases have different thresholds, representing different developmental processes. AILD is relatively rare, and the current study was small; thus, further confirmation is necessary.

These results of LT, FLLs and AILD based on SWE cannot yet be clinically translated, as the research published to date is insufficient to definitively establish diagnostic criteria. However, elastography has shown promise for use in many research and development opportunities and future applications.

Future perspectives

Although there is evidence that 2D-SWE could become a crucial tool in end-stage liver disease, additional research and development are necessary. Additional work should focus on the role of SWE not only in cross-sectional diagnosis but also in longitudinal studies considering disease progression, regression and clinical outcomes^[67]. Priority should be given to multicenter, large-scale verification research. Indeed, the longitudinal monitoring of fibrosis in patients with CLD may be a highly practical application for SWE. Preliminary research has revealed a remarkable decrease in LS values in patients with chronic viral hepatitis after continued antiviral treatment^[68,69]. Given its high patient acceptance and good accessibility, SWE may also become a convenient tool for identifying patients with liver disease and a promising avenue for future research. However, several issues warrant further consideration.

The basic problem

1. Although alternative techniques, such as pSWE/ARFI or 2D-SWE, seem to overcome the limitations of TE, their quality criteria for the staging of liver fibrosis are not yet well defined.

a. It remains unclear whether the shear wave Young's modulus or shear wave velocity is more representative.
b. It remains unknown whether multiple measurements in one location are necessary when satisfactory measures of stiffness are obtained. Or, whether measurements in more than one location are needed.
c. There is currently no agreement on objective quality criteria regarding what constitutes a valid measurement and what is an invalid measurement.

2. It remains unknown whether a simple semi-quantitative fibrosis score can adequately reflect the complexity of the pathophysiological process.

The clinical questions

1. In the era of promotion of precision medicine, can 2D-SWE accurately guide clinical work to aid in the design of an antiviral therapy for hepatitis B patients?
2. Can 2D-SWE be a reliable measurement of the prognosis of liver fibrosis?
3. Does a greater Young's modulus indicate more serious disease progression? Does a reduced Young's modulus indicate disease remission or effective treatment?
4. How do we diagnose the mixed types of liver disease?
5. In adult patients with NAFLD, what SWE LS cut-off value allows us to accurately diagnose the presence of cirrhosis and eliminate the need for liver biopsy?
6. In compensated cirrhosis of adult CLD, what 2D-SWE liver stiffness cut-off value allows us to avoid the need for gastroscopy?
7. Focal lesions can lead to erroneous results. How should these be resolved?

Patient follow-up questions

1. During follow-up monitoring, are there any definite cut-off values to weigh the progression, regression and outcome of liver disease?
2. What is a minimal time span for measuring LS over time? How often should measurements be performed?
3. How should elastography be used to predict the risk for HCC in patients with cirrhosis, regardless of etiology?

Here, we will address the first clinical issue. On the basis of the current study, we believe that SWE can guide clinical work to help develop a reasonable treatment strategy for patients with CLDs by measuring the degree of LS, which reflects the degree of liver fibrosis, and by monitoring the progress of the disease in real time. According to the EASL guidelines, it is of particular significance to identify patients with cirrhosis, as their treatment regimen and posttreatment surveillance must be adapted^[27]. The latest report^[70] from a European, 10-center, cohort study of 1951 adult Caucasian CHB patients found that HCC incidence distinctly dropped after the first 5 years of therapy, particularly in those with compensated cirrhosis. Furthermore, multivariable analysis showed that a $LS \geq 12$ kPa at year 5 was related to greater HCC development after year 5, which likely represents valuable indirect markers of the severity of liver disease. Consequently, we believe that SWE can reflect liver fibrosis and guide therapy, thus decreasing the risk of HCC and remarkably improving the prognosis. This represents a major advancement in the treatment of CLD.

2D-SWE is known to be a multifactorial technique that factors in the anatomy of the liver, the physical characteristics and the underlying illness of the patient, the experience of the examiner, and differences in equipment. The following details include the factors associated with SWE reliability and ways to improve its performance in liver applications.

Anatomy of the liver

The liver is located in the upper abdomen, near the heart, lungs and gastrointestinal tract, and is particularly affected by respiratory movements as well as the heartbeat and gas in the gastrointestinal tract^[71]. Measurements of the left liver lobe yield markedly higher values and are more variable than the right lobe; thus, LSM in the left liver lobe should be avoided whenever possible^[72]. During the examination, the patient needs to cooperate by holding their breath (neither in the expiratory phase nor in the aspirated phase) to stabilize the 2D image measurement because stable 2D imaging is the basis of successful results^[24].

Physical characteristics and underlying illness of the patient

Previous studies have reported that SWE measurements are not affected by a high body mass index, ascites or fatty liver^[20,73], while in clinical practice, high measurement failure rates are due to obesity or ascites causing poor penetration^[4]. Obese patients often have a fatty liver with a thick layer of subcutaneous fat and echo attenuation throughout the liver, which is not conducive to clear 2D imaging. In some very thin patients with a narrow intercostal space, especially patients who have entered the end-stage of liver cirrhosis, the right liver has been severely reduced to the extent that it affects elasticity measurements^[33].

Using current methods, according to the patient's liver, the depth should be dropped, and the image should be appropriately enlarged while the areas of the sampling frame and ROI are adjusted to the shrinking liver. In addition, some factors influence the LS measured by elastography, leading to an overestimation of liver fibrosis^[71,74-78]. Such factors include excessive alcohol intake, elevated central venous pressure, cardiac failure, intra- or extrahepatic cholestasis, alanine aminotransferase flare in acute or chronic hepatitis, and histological necroinflammation activity.

Operator experience

LS measurements by 2D-SWE should be made by an expert operator. It has been reported that experienced examiners have higher reproducibility of measurements than novice examiners^[79,80]. It is advised that at least 50 supervised 2D-SWE measurements should be performed by beginners in order to acquire reliable results^[79]. This issue therefore necessitates strict prejob training for operators to reduce the error caused by lack of experience and to improve the stability of clinical implementations (Figure 5 shows an analysis of failed measurements).

Differences in manufacturer equipment

There may be significant variation in the frequency of acoustic radiation forces used across manufacturers, although variations can even be observed across different equipment from the same manufacturer or due to different settings applied using the same equipment. Large differences among the measurements provided by different settings create obstacles to the clinical application of SWE that need be addressed in the future^[81]. In summary, these techniques need to be performed using a standardized protocol with critically interpreted results, taking confounding factors into account.

CONCLUSION

In conclusion, 2D-SWE appears to be a valid, simple, rapid and reproducible method for the noninvasive assessment of liver fibrosis, with advantages including its low cost and widespread availability. As liver biopsies cannot be performed frequently, SWE can be used to regularly monitor liver fibrosis over the long term. SWE is a promising technology with potential clinical applications, including accurate quantification and therapeutic monitoring. We believe that with the popularity of US elastography, the noninvasive assessment of liver fibrosis will be further promoted. Most importantly, in the future, SWE may become a routine method of screening for patients with CLDs. Finally, large-scale, multicenter, multifield clinical studies are needed to explore the applications of SWE, as there may be variability in terms of demographics, disease and liver cancer incidence predictions. We are




Figure 5 Analysis of failed measurements. A: A 69-year-old female who had right heart failure and could not hold her breath, causing the failed liver stiffness measurement; B: An image acquired by an inexperienced operator who did not set the standard parameters.

hopeful that SWE will continue to evolve and attain a utility equal to that of Doppler as a new mode of US imaging.

REFERENCES

- Singh S, Muir AJ, Dieterich DT, Falck-Ytter YT. American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases. *Gastroenterology* 2017; **152**: 1544-1577 [PMID: 28442120 DOI: 10.1053/j.gastro.2017.03.016]
- GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 2015; **385**: 117-171 [PMID: 25530442 DOI: 10.1016/s0140-6736(14)61682-2]
- Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. *Gut* 2015; **64**: 830-841 [PMID: 25681399 DOI: 10.1136/gutjnl-2014-306842]
- Friedrich-Rust M, Poyndar T, Castera L. Critical comparison of elastography methods to assess chronic liver disease. *Nat Rev Gastroenterol Hepatol* 2016; **13**: 402-411 [PMID: 27273167 DOI: 10.1038/nrgastro.2016.86]
- Stasi C, Milani S. Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness. *World J Gastroenterol* 2016; **22**: 1711-1720 [PMID: 26819535 DOI: 10.3748/wjg.v22.i4.1711]
- Sharma S, Khalili K, Nguyen GC. Non-invasive diagnosis of advanced fibrosis and cirrhosis. *World J Gastroenterol* 2014; **20**: 16820-16830 [PMID: 25492996 DOI: 10.3748/wjg.v20.i45.16820]
- Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, Shiffman ML, Fontana RJ, Di Bisceglie AM, Bonkovsky HL, Dienstag JL; HALT-C Trial Group. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. *Clin Gastroenterol Hepatol* 2010; **8**: 877-883 [PMID: 20362695 DOI: 10.1016/j.cgh.2010.03.025]
- Schiavon Lde L, Narciso-Schiavon JL, de Carvalho-Filho RJ. Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. *World J Gastroenterol* 2014; **20**: 2854-2866 [PMID: 24659877 DOI: 10.3748/wjg.v20.i11.2854]
- Cassinotto C, Lapuyade B, Mouries A, Hiriart JB, Vergniol J, Gaye D, Castain C, Le Bail B, Chermak F, Foucher J, Laurent F, Montaudon M, De Ledinghen V. Non-invasive assessment of liver fibrosis with impulse elastography: comparison of Supersonic Shear Imaging with ARFI and FibroScan®. *J Hepatol* 2014; **61**: 550-557 [PMID: 24815876 DOI: 10.1016/j.jhep.2014.04.044]
- Dietrich CF, Bamber J, Berzigotti A, Bota S, Cantisani V, Castera L, Cosgrove D, Ferraioli G, Friedrich-Rust M, Gilja OH, Goertz RS, Karlas T, de Knecht R, de Ledinghen V, Piscaglia F, Procopet B, Saftoiu A, Sidhu PS, Sporea I, Thiele M. EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version). *Ultraschall Med* 2017; **38**: e16-e47 [PMID: 28407655 DOI: 10.1055/s-0043-103952]
- European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Hgado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. *J Hepatol* 2015; **63**: 237-264 [PMID: 25911335 DOI: 10.1016/j.jhep.2015.04.006]
- Bamber J, Cosgrove D, Dietrich CF, Fromageau J, Bojunga J, Calliada F, Cantisani V, Correas JM, D'Onofrio M, Drakonaki EE, Fink M, Friedrich-Rust M, Gilja OH, Havre RF, Jenssen C, Klausner AS, Ohlinger R, Saftoiu A, Schaefer F, Sporea I, Piscaglia F. EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 1: Basic principles and technology. *Ultraschall Med* 2013; **34**: 169-184 [PMID: 23558397 DOI: 10.1055/s-0033-1335205]
- Castéra L, Foucher J, Bernard PH, Carvalho F, Allaix D, Merrouche W, Couzigou P, de Ledinghen V. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. *Hepatology* 2010; **51**: 828-835 [PMID: 20063276 DOI: 10.1002/hep.23425]
- Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. *Gastroenterology* 2008; **134**: 960-974 [PMID: 18395077 DOI: 10.1053/j.gastro.2008.01.034]
- Haque M, Robinson C, Owen D, Yoshida EM, Harris A. Comparison of acoustic radiation force impulse imaging (ARFI) to liver biopsy histologic scores in the evaluation of chronic liver disease: A pilot study. *Ann Hepatol* 2010; **9**: 289-293 [PMID: 20720270]
- Singh S, Venkatesh SK, Wang Z, Miller FH, Motosugi U, Low RN, Hassanein T, Asbach P, Godfrey EM, Yin M, Chen J, Keaveny AP, Bridges M, Bohte A, Murad MH, Lomas DJ, Talwalkar JA, Ehman RL. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. *Clin Gastroenterol Hepatol* 2015; **13**: 440-451.e6 [PMID: 25305349 DOI: 10.1016/j.cgh.2014.09.046]
- Huwart L, Sempoux C, Vicaute E, Salameh N, Annet L, Danse E, Peeters F, ter Beek LC, Rahier J, Sinkus R, Horsmans Y, Van Beers BE. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. *Gastroenterology* 2008; **135**: 32-40 [PMID: 18471441 DOI: 10.1053/j.gastro.2008.03.076]
- Bavu E, Gennisson JL, Couade M, Bercoff J, Mallet V, Fink M, Badel A, Vallet-Pichard A, Nalpas B, Tanter M, Pol S. Noninvasive in vivo liver fibrosis evaluation using supersonic shear imaging: a clinical study on 113 hepatitis C virus patients. *Ultrasound Med*

- Biol* 2011; **37**: 1361-1373 [PMID: 21775051 DOI: 10.1016/j.ultrasmedbio.2011.05.016]
- 19 **Muller M**, Gennisson JL, Deffieux T, Tanter M, Fink M. Quantitative viscoelasticity mapping of human liver using supersonic shear imaging: preliminary in vivo feasibility study. *Ultrasound Med Biol* 2009; **35**: 219-229 [PMID: 19081665 DOI: 10.1016/j.ultrasmedbio.2008.08.018]
 - 20 **Ferraioli G**, Tinelli C, Dal Bello B, Zicchetti M, Filice G, Filice C; Liver Fibrosis Study Group. Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: a pilot study. *Hepatology* 2012; **56**: 2125-2133 [PMID: 22767302 DOI: 10.1002/hep.25936]
 - 21 **Poynard T**, Munteanu M, Luckina E, Perazzo H, Ngo Y, Royer L, Fedchuk L, Sattouet F, Pais R, Lebray P, Rudler M, Thabut D, Ratzu V. Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard. *J Hepatol* 2013; **58**: 928-935 [PMID: 23321316 DOI: 10.1016/j.jhep.2012.12.021]
 - 22 **Shiina T**, Nightingale KR, Palmeri ML, Hall TJ, Bamber JC, Barr RG, Castera L, Choi BI, Chou YH, Cosgrove D, Dietrich CF, Ding H, Amy D, Farrokhi A, Ferraioli G, Filice C, Friedrich-Rust M, Nakashima K, Schafer F, Sporea I, Suzuki S, Wilson S, Kudo M. WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 1: basic principles and terminology. *Ultrasound Med Biol* 2015; **41**: 1126-1147 [PMID: 25805059 DOI: 10.1016/j.ultrasmedbio.2015.03.009]
 - 23 **Ferraioli G**, Filice C, Castera L, Choi BI, Sporea I, Wilson SR, Cosgrove D, Dietrich CF, Amy D, Bamber JC, Barr R, Chou YH, Ding H, Farrokhi A, Friedrich-Rust M, Hall TJ, Nakashima K, Nightingale KR, Palmeri ML, Schafer F, Shiina T, Suzuki S, Kudo M. WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 3: liver. *Ultrasound Med Biol* 2015; **41**: 1161-1179 [PMID: 25800942 DOI: 10.1016/j.ultrasmedbio.2015.03.007]
 - 24 **Barr RG**, Ferraioli G, Palmeri ML, Goodman ZD, Garcia-Tsao G, Rubin J, Garra B, Myers RP, Wilson SR, Rubens D, Levine D. Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement. *Radiology* 2015; **276**: 845-861 [PMID: 26079489 DOI: 10.1148/radiol.2015150619]
 - 25 **Schweitzer A**, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. *Lancet* 2015; **386**: 1546-1555 [PMID: 26231459 DOI: 10.1016/s0140-6736(15)61412-x]
 - 26 **Petruzzello A**, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. *World J Gastroenterol* 2016; **22**: 7824-7840 [PMID: 27678366 DOI: 10.3748/wjg.v22.i34.7824]
 - 27 **European Association for the Study of the Liver**. Electronic address: easloffice@easloffice.eu.; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. *J Hepatol* 2017; **67**: 370-398 [PMID: 28427875 DOI: 10.1016/j.jhep.2017.03.021]
 - 28 **Rockey DC**. Noninvasive assessment of liver fibrosis and portal hypertension with transient elastography. *Gastroenterology* 2008; **134**: 8-14 [PMID: 18166342 DOI: 10.1053/j.gastro.2007.11.053]
 - 29 **Zeng J**, Liu GJ, Huang ZP, Zheng J, Wu T, Zheng RQ, Lu MD. Diagnostic accuracy of two-dimensional shear wave elastography for the non-invasive staging of hepatic fibrosis in chronic hepatitis B: a cohort study with internal validation. *Eur Radiol* 2014; **24**: 2572-2581 [PMID: 25027837 DOI: 10.1007/s00330-014-3292-9]
 - 30 **European Association For The Study Of The Liver**. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. *J Hepatol* 2012; **57**: 167-185 [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010]
 - 31 **European Association For Study of Liver**. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. *J Hepatol* 2014; **60**: 392-420 [PMID: 24331294 DOI: 10.1016/j.jhep.2013.11.003]
 - 32 **WHO Guidelines Approved by the Guidelines Review Committee**. Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva: World Health Organization Copyright (c) World Health Organization 2015, 2015
 - 33 **Leung VY**, Shen J, Wong VW, Abrigo J, Wong GL, Chim AM, Chu SH, Chan AW, Choi PC, Ahuja AT, Chan HL, Chu WC. Quantitative elastography of liver fibrosis and spleen stiffness in chronic hepatitis B carriers: comparison of shear-wave elastography and transient elastography with liver biopsy correlation. *Radiology* 2013; **269**: 910-918 [PMID: 23912619 DOI: 10.1148/radiol.13130128]
 - 34 **Feng JC**, Li J, Wu XW, Peng XY. Diagnostic Accuracy of SuperSonic Shear Imaging for Staging of Liver Fibrosis: A Meta-analysis. *J Ultrasound Med* 2016; **35**: 329-339 [PMID: 26795041 DOI: 10.7863/ultra.15.03032]
 - 35 **Li C**, Zhang C, Li J, Huo H, Song D. Diagnostic Accuracy of Real-Time Shear Wave Elastography for Staging of Liver Fibrosis: A Meta-Analysis. *Med Sci Monit* 2016; **22**: 1349-1359 [PMID: 27102449 DOI: 10.12659/msm.895662]
 - 36 **Jiang T**, Tian G, Zhao Q, Kong D, Cheng C, Zhong L, Li L. Diagnostic Accuracy of 2D-Shear Wave Elastography for Liver Fibrosis Severity: A Meta-Analysis. *PLoS One* 2016; **11**: e0157219 [PMID: 27300569 DOI: 10.1371/journal.pone.0157219]
 - 37 **Herrmann E**, de Lédinghen V, Cassinotto C, Chu WC, Leung VY, Ferraioli G, Filice C, Castera L, Vilgrain V, Ronot M, Dumortier J, Guibal A, Pol S, Trebicka J, Jansen C, Strassburg C, Zheng R, Zheng J, Francque S, Vanwolleghem T, Vonghia L, Manesis EK, Zoumpoulis P, Sporea I, Thiele M, Krag A, Cohen-Bacrie C, Criton A, Gay J, Deffieux T, Friedrich-Rust M. Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysis. *Hepatology* 2018; **67**: 260-272 [PMID: 28370257 DOI: 10.1002/hep.29179]
 - 38 **Grgurevic I**, Puljiz Z, Brnic D, Bokun T, Heinzl R, Lukic A, Luksic B, Kujundzic M, Brkljacic B. Liver and spleen stiffness and their ratio assessed by real-time two dimensional-shear wave elastography in patients with liver fibrosis and cirrhosis due to chronic viral hepatitis. *Eur Radiol* 2015; **25**: 3214-3221 [PMID: 25903706 DOI: 10.1007/s00330-015-3728-x]
 - 39 **Haga Y**, Kanda T, Sasaki R, Nakamura M, Nakamoto S, Yokosuka O. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis. *World J Gastroenterol* 2015; **21**: 12989-12995 [PMID: 26675364 DOI: 10.3748/wjg.v21.i46.12989]
 - 40 **Younossi ZM**, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 2016; **64**: 73-84 [PMID: 26707365 DOI: 10.1002/hep.28431]
 - 41 **Williams CD**, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. *Gastroenterology* 2011; **140**: 124-131 [PMID: 20858492 DOI: 10.1053/j.gastro.2010.09.038]
 - 42 **Sanyal AJ**, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, Ratzu V, McCullough A. Endpoints and clinical trial design for nonalcoholic steatohepatitis. *Hepatology* 2011; **54**: 344-353 [PMID: 21520200 DOI: 10.1002/hep.24376]
 - 43 **Vernon G**, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Aliment Pharmacol Ther* 2011; **34**: 274-285 [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x]
 - 44 **Singh S**, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. *Clin Gastroenterol Hepatol* 2015; **13**: 643-54.e1-9; quiz e39-40 [PMID: 24768810 DOI: 10.1016/j.cgh.2014.04.014]
 - 45 **Angulo P**, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD,

- Stahler A, Hafliadottir S, Bendtsen F. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology* 2015; **149**: 389-97.e10 [PMID: 25935633 DOI: 10.1053/j.gastro.2015.04.043]
- 46 **Cassinotto C**, Boursier J, de Lédinghen V, Lebigoit J, Lapuyade B, Cales P, Hiriart JB, Michalak S, Bail BL, Cartier V, Mouries A, Oberti F, Fouchard-Hubert I, Vergniol J, Aubé C. Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy. *Hepatology* 2016; **63**: 1817-1827 [PMID: 26659452 DOI: 10.1002/hep.28394]
- 47 **Garcovich M**, Veraldi S, Di Stasio E, Zocco MA, Monti L, Tomà P, Pompili M, Gasbarrini A, Nobili V. Liver Stiffness in Pediatric Patients with Fatty Liver Disease: Diagnostic Accuracy and Reproducibility of Shear-Wave Elastography. *Radiology* 2017; **283**: 820-827 [PMID: 27982761 DOI: 10.1148/radiol.2016161002]
- 48 **Rehm J**, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. *J Hepatol* 2013; **59**: 160-168 [PMID: 23511777 DOI: 10.1016/j.jhep.2013.03.007]
- 49 **Mueller S**, Seitz HK, Rausch V. Non-invasive diagnosis of alcoholic liver disease. *World J Gastroenterol* 2014; **20**: 14626-14641 [PMID: 25356026 DOI: 10.3748/wjg.v20.i40.14626]
- 50 **European Association for the Study of Liver**. EASL clinical practical guidelines: management of alcoholic liver disease. *J Hepatol* 2012; **57**: 399-420 [PMID: 22633836 DOI: 10.1016/j.jhep.2012.04.004]
- 51 **Thiele M**, Dettlfeisen S, Sevelsted Møller L, Madsen BS, Fuglsang Hansen J, Fialla AD, Trebicka J, Krag A. Transient and 2-Dimensional Shear-Wave Elastography Provide Comparable Assessment of Alcoholic Liver Fibrosis and Cirrhosis. *Gastroenterology* 2016; **150**: 123-133 [PMID: 26435270 DOI: 10.1053/j.gastro.2015.09.040]
- 52 **Tripathi D**, Stanley AJ, Hayes PC, Patch D, Millson C, Mehrzad H, Austin A, Ferguson JW, Olliff SP, Hudson M, Christie JM; Clinical Services and Standards Committee of the British Society of Gastroenterology. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. *Gut* 2015; **64**: 1680-1704 [PMID: 25887380 DOI: 10.1136/gutjnl-2015-309262]
- 53 **Kasai Y**, Moriyasu F, Saito K, Hara T, Kobayashi Y, Nakamura I, Sugimoto K. Value of shear wave elastography for predicting hepatocellular carcinoma and esophagogastric varices in patients with chronic liver disease. *J Med Ultrason (2001)* 2015; **42**: 349-355 [PMID: 26576786 DOI: 10.1007/s10396-014-0603-3]
- 54 **Jansen C**, Bogs C, Verlinden W, Thiele M, Möller P, Görtzen J, Lehmann J, Praktiknjo M, Chang J, Krag A, Strassburg CP, Francque S, Trebicka J. Algorithm to rule out clinically significant portal hypertension combining Shear-wave elastography of liver and spleen: a prospective multicentre study. *Gut* 2016; **65**: 1057-1058 [PMID: 26896458 DOI: 10.1136/gutjnl-2016-311536]
- 55 **Procopet B**, Berzigotti A, Abalde JG, Turon F, Hernandez-Gea V, García-Pagán JC, Bosch J. Real-time shear-wave elastography: applicability, reliability and accuracy for clinically significant portal hypertension. *J Hepatol* 2015; **62**: 1068-1075 [PMID: 25514554 DOI: 10.1016/j.jhep.2014.12.007]
- 56 **Maruyama H**, Kobayashi K, Kiyono S, Sekimoto T, Kanda T, Yokosuka O. Two-dimensional shear wave elastography with propagation-based reliability assessment for grading hepatic fibrosis and portal hypertension. *J Hepatobiliary Pancreat Sci* 2016; **23**: 595-602 [PMID: 27440720 DOI: 10.1002/jhpb.379]
- 57 **Wang HK**, Lai YC, Tseng HS, Lee RC, Loong CC, Lin NC, Chou YH, Chiou HC, Chang CY. Hepatic venous congestion after living donor liver transplantation: quantitative assessment of liver stiffness using shear wave elastography--a case report. *Transplant Proc* 2012; **44**: 814-816 [PMID: 22483503 DOI: 10.1016/j.transproceed.2012.01.035]
- 58 **Yoon JH**, Lee JY, Woo HS, Yu MH, Lee ES, Joo I, Lee KB, Yi NJ, Lee YJ, Han JK, Choi BI. Shear wave elastography in the evaluation of rejection or recurrent hepatitis after liver transplantation. *Eur Radiol* 2013; **23**: 1729-1737 [PMID: 23300037 DOI: 10.1007/s00330-012-2748-z]
- 59 **Korda D**, Lenard ZM, Gerlei Z, Jakab Z, Haboub-Sandil A, Wagner L, Varga M, Csepkekal O, Marton A, Horvathy D, Takacs S, Doros A, Mathe Z. Shear-wave elastography for the assessment of liver fibrosis in liver transplant recipients treated for hepatitis C virus recurrence. *Eur J Gastroenterol Hepatol* 2018; **30**: 27-32 [PMID: 29049126 DOI: 10.1097/MEG.0000000000001003]
- 60 **Conti CB**, Cavalcoli F, Fraquelli M, Conte D, Massironi S. Ultrasound elastographic techniques in focal liver lesions. *World J Gastroenterol* 2016; **22**: 2647-2656 [PMID: 26973405 DOI: 10.3748/wjg.v22.i9.2647]
- 61 **Park HS**, Kim YJ, Yu MH, Jung SI, Jeon HJ. Shear Wave Elastography of Focal Liver Lesion: Intraobserver Reproducibility and Elasticity Characterization. *Ultrasound Q* 2015; **31**: 262-271 [PMID: 26086459 DOI: 10.1097/RUQ.0000000000000175]
- 62 **Lu Q**, Ling W, Lu C, Li J, Ma L, Quan J, He D, Liu J, Yang J, Wen T, Wu H, Zhu H, Luo Y. Hepatocellular carcinoma: stiffness value and ratio to discriminate malignant from benign focal liver lesions. *Radiology* 2015; **275**: 880-888 [PMID: 25636031 DOI: 10.1148/radiol.14131164]
- 63 **Brunel T**, Guibal A, Boularan C, Ducerf C, Mabrut JY, Bancel B, Boussel L, Rode A. Focal nodular hyperplasia and hepatocellular adenoma: The value of shear wave elastography for differential diagnosis. *Eur J Radiol* 2015; **84**: 2059-2064 [PMID: 26299323 DOI: 10.1016/j.ejrad.2015.07.029]
- 64 **Grgurevic I**, Bokun T, Salkic NN, Brkljacic B, Vukelić-Markovic M, Stoos-Veic T, Aralica G, Rakic M, Filipce-Kanizaj T, Berzigotti A. Liver elastography malignancy prediction score for noninvasive characterization of focal liver lesions. *Liver Int* 2017; Epub ahead of print [PMID: 29028279 DOI: 10.1111/liv.13611]
- 65 **Carbone M**, Neuberger JM. Autoimmune liver disease, autoimmunity and liver transplantation. *J Hepatol* 2014; **60**: 210-223 [PMID: 24084655 DOI: 10.1016/j.jhep.2013.09.020]
- 66 **Zeng J**, Huang ZP, Zheng J, Wu T, Zheng RQ. Non-invasive assessment of liver fibrosis using two-dimensional shear wave elastography in patients with autoimmune liver diseases. *World J Gastroenterol* 2017; **23**: 4839-4846 [PMID: 28765706 DOI: 10.3748/wjg.v23.i26.4839]
- 67 **Grgurević I**, Bokun T, Mustapić S, Trkulja V, Heinzl R, Banić M, Puljiz Ž, Lukšić B, Kujundžić M. Real-time two-dimensional shear wave ultrasound elastography of the liver is a reliable predictor of clinical outcomes and the presence of esophageal varices in patients with compensated liver cirrhosis. *Croat Med J* 2015; **56**: 470-481 [PMID: 26526884 DOI: 10.3325/cmj.2015.56.470]
- 68 **Marcellin P**, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinis KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. *Lancet* 2013; **381**: 468-475 [PMID: 23234725 DOI: 10.1016/S0140-6736(12)61425-1]
- 69 **Hartl J**, Denzer U, Ehlken H, Zenouzi R, Peiseler M, Sebode M, Hübener S, Pannicke N, Weiler-Normann C, Quas A, Lohse AW, Schramm C. Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis. *J Hepatol* 2016; **65**: 769-775 [PMID: 27238753 DOI: 10.1016/j.jhep.2016.05.023]
- 70 **Papatheodoridis GV**, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, Calleja JL, Sypsa V, Goulis J, Manolakopoulos S, Loglio A, Siakavellas S, Keskin O, Gatselis N, Hansen BE, Lehretz M, de la Revilla J, Savvidou S, Kourikou A, Vlachogiannakos I, Galanis K, Yurdaydin C, Berg T, Colombo M, Esteban R, Janssen HLA, Lampertico P. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. *Hepatology* 2017; **66**: 1444-1453 [PMID: 28622419 DOI: 10.1002/hep.29320]
- 71 **Cosgrove D**, Piscaglia F, Bamber J, Bojunga J, Correias JM, Gilja OH, Klauser AS, Sporea I, Calliada F, Cantisani V, D'Onofrio M, Drakonaki EE, Fink M, Friedrich-Rust M, Fromageau J, Havre RF, Jenssen C, Ohlinger R, Săftoiu A, Schaefer F, Dietrich CF; EFSUMB. EFSUMB guidelines and recommendations

- on the clinical use of ultrasound elastography. Part 2: Clinical applications. *Ultraschall Med* 2013; **34**: 238-253 [PMID: 23605169 DOI: 10.1055/s-0033-1335375]
- 72 **Karlas T**, Pfrepper C, Wiegand J, Wittekind C, Neuschulz M, Mössner J, Berg T, Tröltzsch M, Keim V. Acoustic radiation force impulse imaging (ARFI) for non-invasive detection of liver fibrosis: examination standards and evaluation of interlobe differences in healthy subjects and chronic liver disease. *Scand J Gastroenterol* 2011; **46**: 1458-1467 [PMID: 21916815 DOI: 10.3109/00365521.2011.610004]
 - 73 **Suh CH**, Kim SY, Kim KW, Lim YS, Lee SJ, Lee MG, Lee J, Lee SG, Yu E. Determination of normal hepatic elasticity by using real-time shear-wave elastography. *Radiology* 2014; **271**: 895-900 [PMID: 24555633 DOI: 10.1148/radiol.14131251]
 - 74 **Mueller S**, Millonig G, Sarovska L, Friedrich S, Reimann FM, Pritsch M, Eisele S, Stickel F, Longerich T, Schirmacher P, Seitz HK. Increased liver stiffness in alcoholic liver disease: differentiating fibrosis from steatohepatitis. *World J Gastroenterol* 2010; **16**: 966-972 [PMID: 20180235 DOI: 10.3748/wjg.v16.i8.966]
 - 75 **Millonig G**, Friedrich S, Adolf S, Fonouni H, Golriz M, Mehrabi A, Stiefel P, Pöschl G, Büchler MW, Seitz HK, Mueller S. Liver stiffness is directly influenced by central venous pressure. *J Hepatol* 2010; **52**: 206-210 [PMID: 20022130 DOI: 10.1016/j.jhep.2009.11.018]
 - 76 **Millonig G**, Reimann FM, Friedrich S, Fonouni H, Mehrabi A, Büchler MW, Seitz HK, Mueller S. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. *Hepatology* 2008; **48**: 1718-1723 [PMID: 18836992 DOI: 10.1002/hep.22577]
 - 77 **Arena U**, Vizzutti F, Corti G, Ambu S, Stasi C, Bresci S, Moscarella S, Boddi V, Petrarca A, Laffi G, Marra F, Pinzani M. Acute viral hepatitis increases liver stiffness values measured by transient elastography. *Hepatology* 2008; **47**: 380-384 [PMID: 18095306 DOI: 10.1002/hep.22007]
 - 78 **Fraquelli M**, Rigamonti C, Casazza G, Donato MF, Ronchi G, Conte D, Rumi M, Lampertico P, Colombo M. Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C. *J Hepatol* 2011; **54**: 621-628 [PMID: 21146243 DOI: 10.1016/j.jhep.2010.07.017]
 - 79 **Ferraioli G**, Tinelli C, Zicchetti M, Above E, Poma G, Di Gregorio M, Filice C. Reproducibility of real-time shear wave elastography in the evaluation of liver elasticity. *Eur J Radiol* 2012; **81**: 3102-3106 [PMID: 22749107 DOI: 10.1016/j.ejrad.2012.05.030]
 - 80 **Zhuang Y**, Ding H, Zhang Y, Sun H, Xu C, Wang W. Two-dimensional Shear-Wave Elastography Performance in the Noninvasive Evaluation of Liver Fibrosis in Patients with Chronic Hepatitis B: Comparison with Serum Fibrosis Indexes. *Radiology* 2017; **283**: 873-882 [PMID: 27982760 DOI: 10.1148/radiol.2016160131]
 - 81 **Piscaglia F**, Salvatore V, Mulazzani L, Cantisani V, Colecchia A, Di Donato R, Feliciani C, Ferrarini A, Gamal N, Grasso V, Marasco G, Mazzotta E, Ravaioli F, Ruggieri G, Serio I, Sitouok Nkamgho JF, Serra C, Festi D, Schiavone C, Bolondi L. Differences in liver stiffness values obtained with new ultrasound elastography machines and Fibroscan: A comparative study. *Dig Liver Dis* 2017; **49**: 802-808 [PMID: 28365330 DOI: 10.1016/j.dld.2017.03.001]
 - 82 **Sirli R**, Bota S, Sporea I, Jurchis A, Popescu A, Gradinaru-Tascău O, Szilaski M. Liver stiffness measurements by means of supersonic shear imaging in patients without known liver pathology. *Ultrasound Med Biol* 2013; **39**: 1362-1367 [PMID: 23743106 DOI: 10.1016/j.ultrasmedbio.2013.03.021]
 - 83 **Hudson JM**, Milot L, Parry C, Williams R, Burns PN. Inter- and intra-operator reliability and repeatability of shear wave elastography in the liver: a study in healthy volunteers. *Ultrasound Med Biol* 2013; **39**: 950-955 [PMID: 23453379 DOI: 10.1016/j.ultrasmedbio.2012.12.011]
 - 84 **Wang CZ**, Zheng J, Huang ZP, Xiao Y, Song D, Zeng J, Zheng HR, Zheng RQ. Influence of measurement depth on the stiffness assessment of healthy liver with real-time shear wave elastography. *Ultrasound Med Biol* 2014; **40**: 461-469 [PMID: 24361224 DOI: 10.1016/j.ultrasmedbio.2013.10.021]
 - 85 **Huang Z**, Zheng J, Zeng J, Wang X, Wu T, Zheng R. Normal liver stiffness in healthy adults assessed by real-time shear wave elastography and factors that influence this method. *Ultrasound Med Biol* 2014; **40**: 2549-2555 [PMID: 25282481 DOI: 10.1016/j.ultrasmedbio.2014.05.008]
 - 86 **Yoon JH**, Lee JM, Han JK, Choi BI. Shear wave elastography for liver stiffness measurement in clinical sonographic examinations: evaluation of intraobserver reproducibility, technical failure, and unreliable stiffness measurements. *J Ultrasound Med* 2014; **33**: 437-447 [PMID: 24567455 DOI: 10.7863/ultra.33.3.437]
 - 87 **Franchi-Abella S**, Corno L, Gonzales E, Antoni G, Fabre M, Ducot B, Pariente D, Gennisson JL, Tanter M, Corréas JM. Feasibility and Diagnostic Accuracy of Supersonic Shear-Wave Elastography for the Assessment of Liver Stiffness and Liver Fibrosis in Children: A Pilot Study of 96 Patients. *Radiology* 2016; **278**: 554-562 [PMID: 26305193 DOI: 10.1148/radiol.2015142815]

P- Reviewer: Grgurevic I, Tahiri M, Tantau M **S- Editor:** Gong ZM
L- Editor: Filipodia **E- Editor:** Huang Y





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>



ISSN 1007-9327

